

Pharmaceutical Portal for Poland

2007-08-23

Selvita - new biotechnology firm in Poland

Selvita, a new Polish biotechnology firm, commenced operations in July. Its main goal is to supply complex solutions to the pharmaceutical and biotechnology sectors, so enabling companies to cut the costs of launching innovative compounds on the market, Pawel Przewiezlikowski, Selvita CEO, told *Pharma Poland News*.

The company aims to achieve its goal by utilising know-how that already exists in Polish universities, research institutes etc., but has not yet been commercialised. Thus it plans to cooperate closely with research institutions. Mr Przewiezlikowski will also use his experience obtained in the IT industry, in companies such as Comarch and Interia.

The firm's core business areas will be: molecule discovery and development, bioinformatics (genomics, proteomics, pharmacogenomics, microarrays, clustering, grids, etc.) and contract research (general chemistry and analytical development services for the pharmaceutical industry, lead discovery, compound optimisation, bioanalytical services). In the first stage of development, Selvita envisages that its highest revenues will be sourced from bioinformatics, and that its biggest investment will be in production of biologically active substances.

From the very beginning, Selvita will target both Polish and foreign clients. In the pharmaceutical and biotechnology sectors, the domestic market alone cannot support R&D expenses, so a firm has to operate internationally and sell simultaneously on many markets, Mr Przewiezlikowski believes. Moreover, the Polish market does not comprise enough clients for Selvita.